February 16, 2017 STRICTLY CONFIDENTIAL XTL Biopharmaceuticals Ltd.
Exhibit 10.2
February 16, 2017
STRICTLY CONFIDENTIAL
0 Xxxxxxxxxxx Xxxxxx
Xxxxxxx, Xxxxxx
Attn: Xxxxxx Xxxxxx
Dear Xx. Xxxxxx:
Reference is made to the engagement agreement (the “Engagement Agreement”), dated November 7, 2016, by and between XTL Biopharmaceuticals Ltd. (the “Company”) and Xxxxxx & Xxxxxxx, a unit of X.X. Xxxxxxxxxx & Co., LLC (“Xxxxxx”) pursuant to which Xxxxxx shall serve as the exclusive agent, advisor or underwriter of the Company in any Offering. Defined terms used herein but not defined herein shall have the meanings given to such terms in the Engagement Agreement.
1. The Company and Xxxxxx hereby agree to amend and restate the first sentence of Section B of the Engagement Agreement as follows:
“The term of Xxxxxx’x exclusive engagement will begin on the date hereof and end 180 days following the date hereof (the “Term”).”
Except as expressly set forth above, all of the terms and conditions of the Engagement Agreement shall continue in full force and effect after the execution of this agreement and shall not be in any way changed, modified or superseded by the terms set forth herein.
This agreement may be executed in two or more counterparts and by facsimile or “.pdf” signature or otherwise, and each of such counterparts shall be deemed an original and all of such counterparts together shall constitute one and the same agreement.
[Remainder of page intentionally left blank]
000 Xxxx Xxxxxx x Xxx Xxxx, Xxx Xxxx 00000 | 212.356.0500
Security services provided by X.X. Xxxxxxxxxx & Co., LLC | Member: FINRA/SIPC
IN WITNESS WHEREOF, this agreement is executed as of the date first set forth above.
| Very truly yours, | ||
|
XXXXXX & XXXXXXX, A UNIT OF X.X. XXXXXXXXXX & CO., LLC | ||
| By: | /s/ Xxxxxx Xxxxxxx | |
| Name: Xxxxxx Xxxxxxx | ||
| Title: COO | ||
Accepted and Agreed:
| By: | /s/ Xxxx Xxxxxx | |
| Name: Xxxx Xxxxxx | ||
| Title: CEO |
[Signature Page to XTLB Engagement Agreement Amendment]
